Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Electrospun PLGA-Propolis Scaffolds Regulate Collagen Architecture in Burn Wounds.

International journal of molecular sciences·2026

Same author

Influence of Propolis-Containing Nonwoven PLGA Dressings on Dermatan and Chondroitin Sulfate Dynamics During Burn-Wound Healing.

Pharmaceuticals (Basel, Switzerland)·2026

Same author

Circulating Aggrecan, Biglycan, and Decorin as Biomarkers of Osteoarticular Alterations in Juvenile Idiopathic Arthritis-A Preliminary Study.

International journal of molecular sciences·2025

Same author

Diagnostic Potential of Periostin, Galectin-3 and Tenascin C Serum Measurements in Inflammatory Bowel Disease: Pilot Study.

International journal of molecular sciences·2025

Same author

The Impact of 24-Month Etanercept Therapy on Changes in Adiponectin, Leptin and Tenascin C Levels in the Blood of Children with Juvenile Idiopathic Arthritis.

Pharmaceuticals (Basel, Switzerland)·2025

Same author

The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAR.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Dec 21, 2025

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-α Inhibitors.

Anna Szeremeta¹, Agnieszka Jura-Półtorak¹, Aleksandra Zoń-Giebel²

¹Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, 41-200 Sosnowiec, Poland.

Journal of Clinical Medicine

|May 13, 2020

Summary

Anti-tumor necrosis factor α (anti-TNF-α) therapy improved aggrecan remodeling in female rheumatoid arthritis (RA) patients. Treatment reduced aggrecan fragments and key enzymes, indicating a beneficial impact on cartilage health.

Keywords:

ADAMTS AGC CS846 TIMP-3 aggrecan rheumatoid arthritis tumor necrosis factor-α inhibitors

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

Related Experiment Videos

Last Updated: Dec 21, 2025

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

Area of Science:

Biochemistry
Immunology
Rheumatology

Background:

Rheumatoid arthritis (RA) is characterized by joint inflammation and cartilage degradation.
Aggrecan turnover is dysregulated in RA patients, involving enzymes like ADAMTS-4 and ADAMTS-5.
Anti-tumor necrosis factor α (anti-TNF-α) therapy is a common treatment for RA.

Purpose of the Study:

To evaluate the impact of 15-month anti-TNF-α therapy on aggrecan turnover in female RA patients.
To assess changes in serum levels of aggrecan fragments and related enzymes before and during treatment.

Main Methods:

Serum samples from healthy controls and female RA patients (treated with TNFαI and methotrexate) were analyzed.
Immunoassay methods were used to measure serum levels of CS846, aggrecan fragments (AGC), ADAMTS-4, ADAMTS-5, and TIMP-3.
Ratios of ADAMTS enzymes to TIMP-3 were calculated.

Main Results:

Before treatment, RA patients had higher levels of CS846, AGC, ADAMTS-4, ADAMTS-5, and TIMP-3 compared to healthy subjects.
The ratio of ADAMTS-5 to TIMP-3 was significantly higher in RA patients.
Anti-TNF-α therapy led to increased CS846, decreased AGC, and downregulated ADAMTS-4 and ADAMTS-5 levels, with reduced ADAMTS/TIMP-3 ratios.

Conclusions:

Anti-TNF-α therapy positively influences aggrecan remodeling in female RA patients.
The treatment appears to restore a more balanced aggrecan turnover, potentially mitigating cartilage damage.